Orient Securities Research Report points out that Gan Li Pharmaceutical's performance is steady, and the innovation pipeline is progressing smoothly. Net profit attributable to mother for the first three quarters of 2026 was 858 million yuan, and net profit to mother for the third quarter of a single quarter was 248 million yuan. Domestic formulations are picking up, and international revenues are rapidly being released. The company received an initial payment of 62 million euros from European partner Menarini in October. Revenue contributions for the fourth quarter were dependent on the progress of contract execution and accounting confirmation. The three Chinese phase III studies of Ruda insulin, an ultra-long-lasting basic insulin weekly formulation, have all reached major endpoints. The company disclosed detailed data on two of these studies at the EASD annual meeting. The progress of the follow-up review of boflavin marketing applications and the domestic registration process for Ruda Insulin are worth paying attention to. According to the quarterly report for the year 26, the company's earnings per share for 26-28 were 2.32/2.77/3.33 yuan, respectively. Referring to the company's average price-earnings ratio, the company was given a PE valuation of 28 times in 2027, corresponding to a target price of 77.56 yuan, maintaining a “buy” rating.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.